Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.

ABSTRACT:

Aim

To investigate the impact of telaprevir-based triple therapy on the serum alpha-fetoprotein (AFP) level of chronic hepatitis C patients.

Methods

A total of 210 patients with chronic hepatitis C genotype 1 of high viral load (baseline serum hepatitis C virus RNA > 5.0 log10 IU/mL) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-α (PEG-IFNα), and ribavirin (RBV) for 24 wk (n = 88), or dual therapy with PEG-IFNα and RBV for 48 wk (n = 122). The relationship between virological response and the change in the serum AFP level from baseline to 24 wk after the end of treatment was examined.

Results

No significant difference in mean baseline AFP level was found between the triple and dual therapy groups (8.8 ng/mL vs

SUBMITTER: Takayama K 

PROVIDER: S-EPMC4402319 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature